CLINICAL TRIALS PROFILE FOR AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE
✉ Email this page to a colleague
All Clinical Trials for AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00149084 ↗ | Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori | Unknown status | Yokoyama Foundation for Clinical Pharmacology | Phase 3 | 2003-04-01 | The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy. |
| NCT00149084 ↗ | Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori | Unknown status | Hamamatsu University | Phase 3 | 2003-04-01 | The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy. |
| NCT00281047 ↗ | The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy | Unknown status | Oita University | Phase 2/Phase 3 | 2006-01-01 | FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is assumed to be produced by H. pylori) measured by the urea breath test. FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10 increases the eradication rates by a triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. |
| NCT00281047 ↗ | The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy | Unknown status | Hamamatsu University | Phase 2/Phase 3 | 2006-01-01 | FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is assumed to be produced by H. pylori) measured by the urea breath test. FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10 increases the eradication rates by a triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. |
| NCT00816140 ↗ | Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication | Completed | National Taiwan University Hospital | Phase 4 | 2007-06-01 | Clarithromycin-based triple therapy containing a proton-pump inhibitor (PPI) twice daily, amoxicillin 1g twice daily, and clarithromycin 500 mg twice daily for 7 days is one of the standard firs-line therapy for Helicobacter pylori eradication. However, because of unsatisfactory eradication rate (80-85%), the Maastricht III guideline recommended extending the treatment duration to increase the eradication rate. Recently, levofloxacin (500 mg qd)-based triple therapy has been shown to achieve an eradication rate of 90% for both the first- and second-line treatment for H. pylori eradication. Several studies have demonstrated that high dose (750mg) and short-course (5 days) levofloxacin is as effective and well tolerated as traditional dose (500mg) and course (10 days) for treatment of mild-to-severe community acquired pneumonia. The high dose and short-course therapy has the potential to increase patient compliance and reduce bacterial resistance to fluoroquinolones. However, whether increasing the dosage of levofloxacin from 500mg to 750 mg qd can augment the efficacy of triple therapy in eradication of H. pylori and shorten the duration of therapy remains unknown. Although levofloxacin-based regimen was presumed to be more effective, previous reports pointed the concern that resistance to fluoroquinolone and other antibiotics which susceptible to the pumping efflux of bacteriae would increase among the gut flora. |
| NCT01061437 ↗ | S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori) | Completed | Bill and Melinda Gates Foundation | Phase 3 | 2009-06-01 | The purpose of this study is to compare the effectiveness of three different antibiotic regimens against Helicobacter pylori (H. pylori). |
| NCT01061437 ↗ | S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori) | Completed | Southwest Oncology Group | Phase 3 | 2009-06-01 | The purpose of this study is to compare the effectiveness of three different antibiotic regimens against Helicobacter pylori (H. pylori). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE
Condition Name
Clinical Trial Locations for AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE
Trials by Country
Clinical Trial Progress for AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE
Clinical Trial Phase
Clinical Trial Sponsors for AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE
Sponsor Name
